FDA authorizes Novavax COVID-19 vaccine for first booster dose


Novavax on Wednesday received Food and Drug Administration authorization for a booster dose of its COVID-19 vaccine.

Yet unlike the bivalent mRNA vaccines currently on the market, Novavax’s booster only targets the original strain of the virus, rather than the original strain and the omicron BA.4/BA.5 subvariants.

The company is studying an omicron-specific vaccine, but executives have said they think the current vaccine provides durable protection across different variants of the virus.

Last week, the company said its clinical trial showed a single booster dose given eight to 11 months after a Novavax primary series resulted in increased antibodies against omicron BA.1, BA.2 and the dominant BA.5 subvariant.

The booster was authorized for adults ages 18 and older who can’t take an mRNA vaccine or don’t have access to one, as well as for adults who would otherwise not receive a booster, the company said.

The booster dose is meant to be given at least six months after completion of primary vaccination with any authorized or approved COVID-19 vaccine.

Previously, the Novavax vaccine was used only as a two-dose primary series, given three weeks apart. The new authorization could help increase lagging booster numbers. According to the Centers for Disease Control and Prevention (CDC), only 33 percent of the population has received a booster dose of COVID-19 vaccine.   

“The U.S. now has access to the Novavax COVID-19 Vaccine, Adjuvanted, the first protein-based option, as a booster,” Stanley C. Erck, Novavax president and CEO, said in a statement. “According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults.”

Unlike Pfizer and Moderna, Novavax relies on more traditional vaccine technology, similar to those used to protect against flu and for routine childhood immunizations against whooping cough and meningitis. 

The two-dose vaccine can be stored at normal refrigerator temperatures, making it easier to ship and use. 

While Novavax missed out on the initial wave of COVID-19 vaccinations, company executives said they were always banking on using it as a booster shot.

Once the CDC also signs off, vaccination can begin.

You May Also Like

Half of us can’t recall last time we laughed… and a third haven’t had a giggle in the last MONTH

We might think we are known for our sense of humour. But…

World Health Organization warns ‘we must prepare’ for potential bird flu pandemic

World Health Organization warns ‘we must prepare’ for potential human bird flu…

An anti-woke nightmare! Why the Fawlty Towers remake is a truly nauseating idea | Television

Have you spent the last day or so with an unexplainable stomach…

Lafayette PD search for suspect after mobile home park shooting

LAFAYETTE, Colo. — The Lafayette Police Department is asking for the public’s…

Officer Allegedly Texted Photo of Tyre Nichols After Beating

Demetrius Haley, one of the Memphis police officers who allegedly beat Tyre…

Just 20 million Americans watched Biden’s State of the Union – down from 38.2 million last year

Only around 23 million viewers tuned in to hear President Biden give…

Newly-crowned Miss Texas under fire for anti-Semitic comments

The newly crowned Miss Texas USA came under fire just days after…

House passes bill to end COVID vaccine requirement for foreign air travelers

Legislation that would eliminate a requirement that most foreign travelers arriving in…